Ellibeşinci Yılında Lityumun Öyküsü

Şengül, Cem; Şengül, Ceyhan Balci; Okay, Tuncer; Dilbaz, Nesrin
March 2004
Klinik Psikofarmakoloji Bulteni;Mar2004, Vol. 14 Issue 1, p50
Academic Journal
Lithium was the first effective psychotropic drug avalaible 3-4 years before chlorpromazine and almost a decade before antidepressants. An Australian psychiarist, John Cade, who proposed toxic products in the urine as the cause of mania, coincidentally discovered the antimanic effects of lithium. In 1949, John Cade reported the results of administration of lithium salts to patients with psychotic excitement for the first time. On the 50th anniversary of John Cade's historical article entitled "Lithium salts in the treatment of psychotic excitement", many articles were published and lectures given all over the world to salute this important advance in psychiatry and psychopharmacology. We would like to present the interesting history of lithium and also discuss current findings regarding the clinical usage and mechanism of actions of lithium once more to celebrate the 55th year of its usage in psychiatry.


Related Articles

  • Lithium neurotoxicity at normal therapeutic levels. Bell, A.J.; Cole, A.; Eccleston, D.; Ferrier, I.N. // British Journal of Psychiatry;May93, Vol. 162, p689 

    Four cases of lithium-induced neurotoxicity are presented which, taken with evidence from previous reports, indicate that specific risk factors for lithium-induced neurotoxicity at normal serum levels are rapid dosage regimes, concomitant neuroleptic therapy, pre-existing EEG abnormalities,...

  • Pharmacotherapy for bipolar disorder and concordance with treatment guidelines: survey of a general population sample referred to a tertiary care service. Paterniti, Sabrina; Bisserbe, Jean-Claude // BMC Psychiatry;2013, Vol. 13 Issue 1, p1 

    Background: Many new approaches have been adopted for the treatment of bipolar disorder (BD) in the past few years, which strived to produce more positive outcomes. To enhance the quality of care, several guideline recommendations have been developed. For study purposes, we monitored the...

  • Mania induced by lithium augmentation. A case report. Yuvarajan, R.; Yousufzai, N. M. // British Journal of Psychiatry;Dec88, Vol. 153, p828 

    A case of mania subsequent to the addition of lithium in unsuccessful treatment by antidepressants is presented. It is suggested that lithium might potentiate some properties of antidepressants which affect their capacity to induce mania.

  • Two variants in Ankyrin 3 (ANK3) are independent genetic risk factors for bipolar disorder. Schulze, T. G.; Detera-Wadleigh, S. D.; Akula, N.; Gupta, A.; Kassem, L.; Steele, J.; Pearl, J.; Strohmaier, J.; Breuer, R.; Schwarz, M.; Propping, P.; Nöthen, M. M.; Cichon, S.; Schumacher, J.; Rietschel, M.; McMahon, F. J. // Molecular Psychiatry;May2009, Vol. 14 Issue 5, p487 

    Two recent reports have highlighted ANK3 as a susceptibility gene for bipolar disorder (BD). We first reported association between BD and the ANK3 marker rs9804190 in a genome-wide association study (GWAS) of two independent samples (Baum et al., 2008). Subsequently, a meta-analysis of GWAS data...

  • Mania in the elderly. Stone, Kit; Stone, K // British Journal of Psychiatry;Aug89, Vol. 155, p220 

    A retrospective study of 92 patients admitted with mania, aged over 65 years of age, found that 26% had no prior history of affective illness; 30% had previously only experienced depression, and half of these had at least three episodes of depression before the first manic illness. Patients with...

  • Depot antipsychotics in the prophylaxis of bipolar affective disorder. Littlejohn, A.; Leslie, F.; Cookson, J.; Littlejohn, R // British Journal of Psychiatry;Dec94, Vol. 165, p827 

    Background: The efficacy of depot antipsychotic drugs in the prophylaxis of bipolar affective disorder was investigated.Method: Life charts were constructed for 18 outpatients with bipolar disorder receiving prophylactic treatment with depot medication. The durations of...

  • Comparison of the prophylactic action of flupenthixol with placebo in lithium treated manic-depressive patients. Esparon, J.; Kolloori, J.; Naylor, G. J.; Smith, A. M.; Hopwood, S. E.; McHarg, A M; Smith, A H // British Journal of Psychiatry;Jun86, Vol. 148, p723 

    A double-blind cross-over trial of depot flupenthixol in recurrent manic depressive psychosis was carried out. All patients continued on lithium. Eleven patients completed the two-year trial. Flupenthixol appeared to have no prophylactic effect.

  • Priadel.  // Royal Society of Medicine: Medicines;2002, p451 

    The article presents information on priadel, a proprietary, prescription only preparation of the anti-mania drug lithium. The drug can be used to treat acute mania, manic depressive bouts and recurrent depression. It is available as tablets or a sugar-free liquid preparation.

  • Add-on quetiapine for bipolar depression: a 12-month open-label trial. Milev, Roumen; Abraham, Gebrehiwot; Zaheer, Juveria // Canadian Journal of Psychiatry;Jul2006, Vol. 51 Issue 8, p523 

    Objectives: Bipolar disorder (BD) is a disabling and often chronic condition. Patients with BD suffer from depression at least one-third of the time, but they do not always respond well to conventional mood stabilizers. Attempts to treat them with antidepressants can provoke a...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics